Table 2.
Univariate | Multivariate | |||
---|---|---|---|---|
Hazard ratio (95% CI) | p value | Hazard ratio (95% CI) | p value | |
Age, years | 1.029 (0.993–1.067) | 0.119 | ||
Male sex | 1.346 (0.633–2.862) | 0.440 | ||
Body mass index, kg/m2 | 0.996 (0.920–1.078) | 0.913 | ||
Hypertension | 0.975 (0.459–2.071) | 0.947 | ||
Dyslipidemia | 0.931 (0.446–1.944) | 0.850 | ||
Current Smoker | 1.570 (0.722–3.416) | 0.441 | ||
β-blocker | 0.503 (0.152–1.662) | 0.255 | ||
Calcium channel blocker | 1.507 (0.736–3.085) | 0.262 | ||
ACE-I or ARB | 0.956 (0.471–1.939) | 0.900 | ||
Statin | 0.669 (0.321–1.398) | 0.285 | ||
Insulin therapy | 0.807 (0.348–1.876) | 0.619 | ||
Oral antihyperglycemic drugs | 0.849 (0.420–1.719) | 0.650 | ||
Metformin | 0.411 (0.125–1.353) | 0.143 | ||
Alpha glucosidase inhibitor | 0.335 (0.080–1.406) | 0.135 | ||
DPP4 inhibitor | 1.247 (0.603–2.578) | 0.551 | ||
eGFR, mL/min/1.73 m2 | 0.999 (0.979–1.019) | 0.908 | ||
Total cholesterol, mg/dL | 1.006 (0.995–1.018) | 0.273 | ||
LDL-cholesterol, mg/dL | 1.015 (1.002–1.029) | 0.023 | 1.018 (1.005–1.032) | 0.005 |
HDL-cholesterol, mg/dL | 0.991 (0.968–1.015) | 0.468 | ||
Ln (triglyceride) | 1.050 (0.531–2.078) | 0.889 | ||
HbA1c, % | 1.029 (0.804–1.317) | 0.813 | ||
Ln (CACS + 1) | 1.311 (1.109–1.549) | 0.002 | ||
Pericardial fat volume, mL | 1.002 (0.996–1.008) | 0.536 | ||
Significant stenosis | 4.750 (2.157–10.264) | < 0.001 | 4.286 (1.764–10.417) | 0.001 |
High-risk plaque | 2.850 (1.404–5.786) | 0.004 | 2.076 (0.935–4.612) | 0.073 |
High LAD-PCAT attenuation | 2.562 (1.202–5.460) | 0.015 | 2.689 (1.166–6.199) | 0.026 |
Suita score | 1.060 (1.019–1.102) | 0.004 |
ACE-I angiotensin-converting enzyme inhibitor; ARB angiotensin-receptor blocker; DPP4 dipeptidyl peptidase-4; eGFR estimated glomerular filtration rate; LDL low-density lipoprotein; HDL high-density lipoprotein; HbA1c glycated hemoglobin A1c; CACS coronary artery calcium score; LAD left anterior descending artery; PCAT pericoronary adipose tissue